Genmab A/S’s €20 Million Share Acquisition In CureVac AG

Simmons & Simmons has advised Danish biotechnology company Genmab A/S on its acquisition of shares in CureVac AG, to the amount of €20m.

CureVac is a highly specialized company headquartered in Tübingen, Germany, conducting research and development into mRNA technology and related drugs in the field of oncology, vaccines and rare diseases. Through such technology, CureVac is able to directly give the body the information it needs to fight and cure diseases.

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.

Genmab has alliances with top tier pharmaceutical and biotechnology companies and the acquisition of shares in CureVac will strengthen the company’s ability to further develop world-leading treatments and cures.

The Simmons team advising on the legal aspects of this deal was led by M&A partner Dr Stephan Ulrich (Picture) and IP partner Dr Peter Meyer from the firm’s office in Düsseldorf, supported by co-lead Counsel Slaven Kovacevic and Supervising Associate Sabine Krause.

Involved fees earner: Slaven Kovacevic – Simmons & Simmons; Sabine Krause – Simmons & Simmons; Peter Meyer – Simmons & Simmons; Stephan Ulrich – Simmons & Simmons;

Law Firms: Simmons & Simmons;

Clients: Genmab A/S;